Page last updated: 2024-11-01

ofloxacin and Sarcoidosis

ofloxacin has been researched along with Sarcoidosis in 1 studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Sarcoidosis: An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.

Research Excerpts

ExcerptRelevanceReference
"Sarcoidosis is a chronic granulomatous disease for which there are limited therapeutic options."2.78Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. ( Aboud, C; Algood, H; Boyd, AS; Braun, N; Burke, VE; Drake, WP; Isom, J; Kaminski, N; King, LE; Oswald-Richter, K; Pandit, KV; Richmond, BW; Taylor, T; Yu, C, 2013)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Drake, WP1
Oswald-Richter, K1
Richmond, BW1
Isom, J1
Burke, VE1
Algood, H1
Braun, N1
Taylor, T1
Pandit, KV1
Aboud, C1
Yu, C1
Kaminski, N1
Boyd, AS1
King, LE1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I/II Study of the Effects of Antibiotics on Sarcoidosis Pathogenesis[NCT01074554]Phase 1/Phase 230 participants (Actual)Interventional2010-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions

(NCT01074554)
Timeframe: Baseline to 8 weeks

Interventionmm (Median)
Antibiotic Regimen-8.4
Placebo Regimen0.07

Change in Modified Sarcoidosis Activity and Severity Index (SASI) at Completion of Therapy.

Characterization of lesion severity was conducted using Modified Sarcoidosis Activity and Severity Index (SASI), measuring erythema, induration and desquamation. The modification was that the same scale was applied to any part of the body, instead of the face alone. The scale range is 0 (no problem) to 72 (very severe). (NCT01074554)
Timeframe: Baseline to 8 weeks

Interventionunits on a scale (Mean)
Antibiotic Regimen-2.9
Placebo Regimen-0.6

Granuloma Burden

Number of patients with a decrease in Granuloma Burden (only in those patients having granulomas present at baseline biopsy) (NCT01074554)
Timeframe: Baseline to 8 weeks

Interventionparticipants (Number)
Antibiotic Regimen7
Placebo Regimen0

Trials

1 trial available for ofloxacin and Sarcoidosis

ArticleYear
Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study.
    JAMA dermatology, 2013, Volume: 149, Issue:9

    Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Azithromycin; CD4-Positive T-Lymphocytes;

2013